Biotech News

Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

Ardelyx (ARDX)ArdelyxConference / presentation

Ardelyx Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET.

Related news

Ardelyx

NHE3 Inhibition Platform Ardelyx develops and commercializes medicines based on inhibition of the sodium-hydrogen exchanger 3 in the gastrointestinal tract. Its approach changes intestinal sodium transport and can affect bowel function and phosphate absorption. IBSRELA and XPHOZAH IBSRELA is approved for irritable bowel syndrome with...

Recent company news

Stock data

Close
3.06 USD
Market cap
1.36B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States